Hansa Biopharma AB (OSTO:HNSA) Interest Expense: kr-144.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
49 GF Score
Price kr33.68
GF Value kr24.46
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Interest Expense?

Hansa Biopharma AB OSTO:HNSA -1.41% 49 Interest Expense is kr-144.1 Mil as of Mar. 2026. GuruFocus rates OSTO:HNSA with a GF Score™ of 49/100 and a GF Value™ of kr24.46 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hansa Biopharma AB's interest expense for the three months ended in Mar. 2026 was kr -55.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-144.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hansa Biopharma AB's Operating Income for the three months ended in Mar. 2026 was kr -142.5 Mil. Hansa Biopharma AB's Interest Expense for the three months ended in Mar. 2026 was kr -55.9 Mil. Hansa Biopharma AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hansa Biopharma AB  (OSTO:HNSA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hansa Biopharma AB's Interest Expense for the three months ended in Mar. 2026 was kr-55.9 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr-142.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr1,135.9 Mil.

Hansa Biopharma AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Hansa Biopharma AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Hansa Biopharma AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Interest Expense Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -43.67 -105.52 -134.08 -121.93

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.28 -13.32 -10.23 -64.59 -55.92
OSTO:HNSA
49GF Score
Hansa Biopharma AB OSTO:HNSA
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-144.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-144.1 Mil mean?
Hansa Biopharma AB (OSTO:HNSA) has a Interest Expense of kr-144.1 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Interest Expense too high?
Hansa Biopharma AB's current Interest Expense is kr-144.1 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Interest Expense compare to VRTX and REGN?
Hansa Biopharma AB's Interest Expense of kr-144.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Interest Expense is kr-144.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.46, compared to a current price of kr33.68 — trading 37.7% above its estimated fair value. The current Interest Expense is kr-144.1 Mil. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Interest Expense is kr-144.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr33.68 is trading 37.7% above its estimated GF Value™ of kr24.46. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • Interest Expense: kr-144.1 Mil
  • GF Value™: kr24.46 vs. price of kr33.68 (37.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for OSTO:HNSA

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.68
Price
kr24.46
GF Value